nodes	percent_of_prediction	percent_of_DWPC	metapath
Montelukast—CYP2A6—esophageal cancer	0.471	0.566	CbGaD
Montelukast—PTGS1—esophageal cancer	0.361	0.434	CbGaD
Montelukast—Tonsillitis—Capecitabine—esophageal cancer	0.00232	0.0408	CcSEcCtD
Montelukast—CYSLTR1—bronchus—esophageal cancer	0.00161	0.123	CbGeAlD
Montelukast—CYSLTR1—smooth muscle tissue—esophageal cancer	0.00157	0.121	CbGeAlD
Montelukast—Hepatitis cholestatic—Capecitabine—esophageal cancer	0.00145	0.0256	CcSEcCtD
Montelukast—CYSLTR1—lung—esophageal cancer	0.00104	0.0795	CbGeAlD
Montelukast—Rhinorrhoea—Cisplatin—esophageal cancer	0.000981	0.0173	CcSEcCtD
Montelukast—ALOX5—bronchus—esophageal cancer	0.000973	0.0746	CbGeAlD
Montelukast—Infection—Carboplatin—esophageal cancer	0.00096	0.0169	CcSEcCtD
Montelukast—ALOX5—smooth muscle tissue—esophageal cancer	0.000952	0.073	CbGeAlD
Montelukast—Liver injury—Cisplatin—esophageal cancer	0.000944	0.0166	CcSEcCtD
Montelukast—Leukocytoclastic vasculitis—Methotrexate—esophageal cancer	0.000889	0.0156	CcSEcCtD
Montelukast—Pain—Carboplatin—esophageal cancer	0.000826	0.0145	CcSEcCtD
Montelukast—Laryngitis—Capecitabine—esophageal cancer	0.000812	0.0143	CcSEcCtD
Montelukast—Hepatocellular injury—Cisplatin—esophageal cancer	0.000794	0.014	CcSEcCtD
Montelukast—Wheezing—Cisplatin—esophageal cancer	0.000771	0.0136	CcSEcCtD
Montelukast—Body temperature increased—Carboplatin—esophageal cancer	0.000764	0.0134	CcSEcCtD
Montelukast—Otitis media—Capecitabine—esophageal cancer	0.000752	0.0132	CcSEcCtD
Montelukast—ALOX5—digestive system—esophageal cancer	0.000752	0.0576	CbGeAlD
Montelukast—Memory impairment—Capecitabine—esophageal cancer	0.000746	0.0131	CcSEcCtD
Montelukast—Neuropathy—Cisplatin—esophageal cancer	0.000746	0.0131	CcSEcCtD
Montelukast—Rhinorrhoea—Capecitabine—esophageal cancer	0.000723	0.0127	CcSEcCtD
Montelukast—CYSLTR1—lymph node—esophageal cancer	0.000709	0.0544	CbGeAlD
Montelukast—Contusion—Capecitabine—esophageal cancer	0.000671	0.0118	CcSEcCtD
Montelukast—Liver disorder—Methotrexate—esophageal cancer	0.00064	0.0113	CcSEcCtD
Montelukast—ALOX5—lung—esophageal cancer	0.000628	0.0481	CbGeAlD
Montelukast—SLCO2B1—digestive system—esophageal cancer	0.000579	0.0444	CbGeAlD
Montelukast—CYP2A6—lung—esophageal cancer	0.000554	0.0424	CbGeAlD
Montelukast—Irritability—Cisplatin—esophageal cancer	0.00055	0.00968	CcSEcCtD
Montelukast—Neuropathy—Capecitabine—esophageal cancer	0.00055	0.00967	CcSEcCtD
Montelukast—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000519	0.00914	CcSEcCtD
Montelukast—Cramp muscle—Cisplatin—esophageal cancer	0.000519	0.00914	CcSEcCtD
Montelukast—Nasopharyngitis—Cisplatin—esophageal cancer	0.000516	0.00907	CcSEcCtD
Montelukast—Ear pain—Capecitabine—esophageal cancer	0.000498	0.00877	CcSEcCtD
Montelukast—Sleep disorder—Capecitabine—esophageal cancer	0.000491	0.00864	CcSEcCtD
Montelukast—Pancreatitis—Cisplatin—esophageal cancer	0.000489	0.0086	CcSEcCtD
Montelukast—SLCO2B1—lung—esophageal cancer	0.000483	0.0371	CbGeAlD
Montelukast—Bone disorder—Methotrexate—esophageal cancer	0.000483	0.00849	CcSEcCtD
Montelukast—Gastroenteritis—Capecitabine—esophageal cancer	0.00048	0.00844	CcSEcCtD
Montelukast—Thirst—Capecitabine—esophageal cancer	0.000447	0.00786	CcSEcCtD
Montelukast—Vasculitis—Methotrexate—esophageal cancer	0.000447	0.00786	CcSEcCtD
Montelukast—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000436	0.00766	CcSEcCtD
Montelukast—Conjunctivitis—Cisplatin—esophageal cancer	0.000432	0.0076	CcSEcCtD
Montelukast—ALOX5—lymph node—esophageal cancer	0.000429	0.0329	CbGeAlD
Montelukast—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00042	0.00739	CcSEcCtD
Montelukast—Irritability—Capecitabine—esophageal cancer	0.000406	0.00714	CcSEcCtD
Montelukast—PTGS1—epithelium—esophageal cancer	0.000397	0.0304	CbGeAlD
Montelukast—Urinary tract disorder—Cisplatin—esophageal cancer	0.000394	0.00693	CcSEcCtD
Montelukast—Connective tissue disorder—Cisplatin—esophageal cancer	0.000392	0.0069	CcSEcCtD
Montelukast—Urethral disorder—Cisplatin—esophageal cancer	0.000391	0.00688	CcSEcCtD
Montelukast—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000383	0.00673	CcSEcCtD
Montelukast—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000383	0.00673	CcSEcCtD
Montelukast—PTGS1—smooth muscle tissue—esophageal cancer	0.000382	0.0293	CbGeAlD
Montelukast—Nasopharyngitis—Capecitabine—esophageal cancer	0.00038	0.00669	CcSEcCtD
Montelukast—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000375	0.0066	CcSEcCtD
Montelukast—Cardiac disorder—Cisplatin—esophageal cancer	0.00037	0.00651	CcSEcCtD
Montelukast—Asthma—Capecitabine—esophageal cancer	0.000367	0.00646	CcSEcCtD
Montelukast—Influenza—Capecitabine—esophageal cancer	0.000367	0.00646	CcSEcCtD
Montelukast—Immune system disorder—Cisplatin—esophageal cancer	0.00036	0.00634	CcSEcCtD
Montelukast—Mediastinal disorder—Cisplatin—esophageal cancer	0.00036	0.00633	CcSEcCtD
Montelukast—Bronchitis—Capecitabine—esophageal cancer	0.000353	0.00622	CcSEcCtD
Montelukast—PTGS1—trachea—esophageal cancer	0.000351	0.0269	CbGeAlD
Montelukast—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000341	0.00601	CcSEcCtD
Montelukast—Muscle spasms—Cisplatin—esophageal cancer	0.000334	0.00587	CcSEcCtD
Montelukast—SLCO2B1—lymph node—esophageal cancer	0.000331	0.0253	CbGeAlD
Montelukast—CYP2C9—digestive system—esophageal cancer	0.000331	0.0253	CbGeAlD
Montelukast—Pneumonia—Capecitabine—esophageal cancer	0.000329	0.0058	CcSEcCtD
Montelukast—Infestation—Capecitabine—esophageal cancer	0.000328	0.00576	CcSEcCtD
Montelukast—Infestation NOS—Capecitabine—esophageal cancer	0.000328	0.00576	CcSEcCtD
Montelukast—Tremor—Cisplatin—esophageal cancer	0.000325	0.00572	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000325	0.00571	CcSEcCtD
Montelukast—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000321	0.00565	CcSEcCtD
Montelukast—Jaundice—Capecitabine—esophageal cancer	0.000319	0.00562	CcSEcCtD
Montelukast—Conjunctivitis—Capecitabine—esophageal cancer	0.000318	0.0056	CcSEcCtD
Montelukast—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00031	0.00545	CcSEcCtD
Montelukast—Epistaxis—Capecitabine—esophageal cancer	0.000309	0.00544	CcSEcCtD
Montelukast—Irritability—Methotrexate—esophageal cancer	0.000302	0.00531	CcSEcCtD
Montelukast—PTGS1—digestive system—esophageal cancer	0.000302	0.0231	CbGeAlD
Montelukast—Convulsion—Cisplatin—esophageal cancer	0.000301	0.00529	CcSEcCtD
Montelukast—Myalgia—Cisplatin—esophageal cancer	0.000296	0.0052	CcSEcCtD
Montelukast—Rhinitis—Capecitabine—esophageal cancer	0.000295	0.00519	CcSEcCtD
Montelukast—Anxiety—Cisplatin—esophageal cancer	0.000295	0.00518	CcSEcCtD
Montelukast—Hepatitis—Capecitabine—esophageal cancer	0.000294	0.00517	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000294	0.00517	CcSEcCtD
Montelukast—Hypoaesthesia—Capecitabine—esophageal cancer	0.000293	0.00515	CcSEcCtD
Montelukast—Pharyngitis—Capecitabine—esophageal cancer	0.000292	0.00514	CcSEcCtD
Montelukast—Urinary tract disorder—Capecitabine—esophageal cancer	0.00029	0.00511	CcSEcCtD
Montelukast—Connective tissue disorder—Capecitabine—esophageal cancer	0.000289	0.00508	CcSEcCtD
Montelukast—Urethral disorder—Capecitabine—esophageal cancer	0.000288	0.00507	CcSEcCtD
Montelukast—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000285	0.00501	CcSEcCtD
Montelukast—Oedema—Cisplatin—esophageal cancer	0.000283	0.00499	CcSEcCtD
Montelukast—Anaphylactic shock—Cisplatin—esophageal cancer	0.000283	0.00499	CcSEcCtD
Montelukast—Infection—Cisplatin—esophageal cancer	0.000282	0.00495	CcSEcCtD
Montelukast—Erythema multiforme—Capecitabine—esophageal cancer	0.000278	0.00489	CcSEcCtD
Montelukast—Nervous system disorder—Cisplatin—esophageal cancer	0.000278	0.00489	CcSEcCtD
Montelukast—Thrombocytopenia—Cisplatin—esophageal cancer	0.000277	0.00488	CcSEcCtD
Montelukast—Skin disorder—Cisplatin—esophageal cancer	0.000275	0.00484	CcSEcCtD
Montelukast—Asthma—Methotrexate—esophageal cancer	0.000273	0.00481	CcSEcCtD
Montelukast—Cardiac disorder—Capecitabine—esophageal cancer	0.000273	0.0048	CcSEcCtD
Montelukast—Eosinophilia—Methotrexate—esophageal cancer	0.000271	0.00476	CcSEcCtD
Montelukast—Pancreatitis—Methotrexate—esophageal cancer	0.000268	0.00472	CcSEcCtD
Montelukast—Immune system disorder—Capecitabine—esophageal cancer	0.000266	0.00467	CcSEcCtD
Montelukast—Mediastinal disorder—Capecitabine—esophageal cancer	0.000265	0.00466	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000258	0.00454	CcSEcCtD
Montelukast—Mental disorder—Capecitabine—esophageal cancer	0.000258	0.00453	CcSEcCtD
Montelukast—Paraesthesia—Cisplatin—esophageal cancer	0.000254	0.00448	CcSEcCtD
Montelukast—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000254	0.00447	CcSEcCtD
Montelukast—CYP3A4—digestive system—esophageal cancer	0.000252	0.0193	CbGeAlD
Montelukast—PTGS1—lung—esophageal cancer	0.000252	0.0193	CbGeAlD
Montelukast—Muscle spasms—Capecitabine—esophageal cancer	0.000246	0.00433	CcSEcCtD
Montelukast—Pneumonia—Methotrexate—esophageal cancer	0.000245	0.00432	CcSEcCtD
Montelukast—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000245	0.00431	CcSEcCtD
Montelukast—Infestation NOS—Methotrexate—esophageal cancer	0.000244	0.00429	CcSEcCtD
Montelukast—Infestation—Methotrexate—esophageal cancer	0.000244	0.00429	CcSEcCtD
Montelukast—Drowsiness—Methotrexate—esophageal cancer	0.000244	0.00429	CcSEcCtD
Montelukast—Pain—Cisplatin—esophageal cancer	0.000242	0.00426	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000242	0.00425	CcSEcCtD
Montelukast—Tremor—Capecitabine—esophageal cancer	0.00024	0.00422	CcSEcCtD
Montelukast—Conjunctivitis—Methotrexate—esophageal cancer	0.000237	0.00417	CcSEcCtD
Montelukast—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000231	0.00406	CcSEcCtD
Montelukast—Epistaxis—Methotrexate—esophageal cancer	0.00023	0.00405	CcSEcCtD
Montelukast—Palpitations—Capecitabine—esophageal cancer	0.000226	0.00398	CcSEcCtD
Montelukast—Body temperature increased—Cisplatin—esophageal cancer	0.000224	0.00394	CcSEcCtD
Montelukast—Cough—Capecitabine—esophageal cancer	0.000223	0.00393	CcSEcCtD
Montelukast—Hepatitis—Methotrexate—esophageal cancer	0.000219	0.00385	CcSEcCtD
Montelukast—Myalgia—Capecitabine—esophageal cancer	0.000218	0.00383	CcSEcCtD
Montelukast—Arthralgia—Capecitabine—esophageal cancer	0.000218	0.00383	CcSEcCtD
Montelukast—Pharyngitis—Methotrexate—esophageal cancer	0.000217	0.00382	CcSEcCtD
Montelukast—Anxiety—Capecitabine—esophageal cancer	0.000217	0.00382	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000216	0.00381	CcSEcCtD
Montelukast—Urinary tract disorder—Methotrexate—esophageal cancer	0.000216	0.0038	CcSEcCtD
Montelukast—Urethral disorder—Methotrexate—esophageal cancer	0.000215	0.00378	CcSEcCtD
Montelukast—Oedema—Capecitabine—esophageal cancer	0.000209	0.00368	CcSEcCtD
Montelukast—Hypersensitivity—Cisplatin—esophageal cancer	0.000209	0.00367	CcSEcCtD
Montelukast—Infection—Capecitabine—esophageal cancer	0.000208	0.00365	CcSEcCtD
Montelukast—Erythema multiforme—Methotrexate—esophageal cancer	0.000207	0.00364	CcSEcCtD
Montelukast—Nervous system disorder—Capecitabine—esophageal cancer	0.000205	0.0036	CcSEcCtD
Montelukast—Thrombocytopenia—Capecitabine—esophageal cancer	0.000205	0.0036	CcSEcCtD
Montelukast—Asthenia—Cisplatin—esophageal cancer	0.000203	0.00358	CcSEcCtD
Montelukast—Cardiac disorder—Methotrexate—esophageal cancer	0.000203	0.00357	CcSEcCtD
Montelukast—Skin disorder—Capecitabine—esophageal cancer	0.000203	0.00357	CcSEcCtD
Montelukast—Immune system disorder—Methotrexate—esophageal cancer	0.000198	0.00348	CcSEcCtD
Montelukast—Mediastinal disorder—Methotrexate—esophageal cancer	0.000197	0.00347	CcSEcCtD
Montelukast—Diarrhoea—Cisplatin—esophageal cancer	0.000194	0.00341	CcSEcCtD
Montelukast—Mental disorder—Methotrexate—esophageal cancer	0.000192	0.00337	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00019	0.00335	CcSEcCtD
Montelukast—Insomnia—Capecitabine—esophageal cancer	0.000189	0.00332	CcSEcCtD
Montelukast—Paraesthesia—Capecitabine—esophageal cancer	0.000188	0.0033	CcSEcCtD
Montelukast—Dyspepsia—Capecitabine—esophageal cancer	0.000184	0.00324	CcSEcCtD
Montelukast—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00018	0.00317	CcSEcCtD
Montelukast—Vomiting—Cisplatin—esophageal cancer	0.00018	0.00317	CcSEcCtD
Montelukast—Fatigue—Capecitabine—esophageal cancer	0.00018	0.00317	CcSEcCtD
Montelukast—Rash—Cisplatin—esophageal cancer	0.000179	0.00314	CcSEcCtD
Montelukast—Pain—Capecitabine—esophageal cancer	0.000179	0.00314	CcSEcCtD
Montelukast—Dermatitis—Cisplatin—esophageal cancer	0.000179	0.00314	CcSEcCtD
Montelukast—PTGS1—lymph node—esophageal cancer	0.000172	0.0132	CbGeAlD
Montelukast—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000171	0.00301	CcSEcCtD
Montelukast—Nausea—Cisplatin—esophageal cancer	0.000168	0.00296	CcSEcCtD
Montelukast—Cough—Methotrexate—esophageal cancer	0.000166	0.00293	CcSEcCtD
Montelukast—Urticaria—Capecitabine—esophageal cancer	0.000166	0.00292	CcSEcCtD
Montelukast—Body temperature increased—Capecitabine—esophageal cancer	0.000165	0.00291	CcSEcCtD
Montelukast—Abdominal pain—Capecitabine—esophageal cancer	0.000165	0.00291	CcSEcCtD
Montelukast—Convulsion—Methotrexate—esophageal cancer	0.000165	0.00291	CcSEcCtD
Montelukast—Myalgia—Methotrexate—esophageal cancer	0.000162	0.00285	CcSEcCtD
Montelukast—Arthralgia—Methotrexate—esophageal cancer	0.000162	0.00285	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000161	0.00283	CcSEcCtD
Montelukast—Anaphylactic shock—Methotrexate—esophageal cancer	0.000156	0.00274	CcSEcCtD
Montelukast—Infection—Methotrexate—esophageal cancer	0.000155	0.00272	CcSEcCtD
Montelukast—Hypersensitivity—Capecitabine—esophageal cancer	0.000154	0.00271	CcSEcCtD
Montelukast—Nervous system disorder—Methotrexate—esophageal cancer	0.000153	0.00268	CcSEcCtD
Montelukast—Thrombocytopenia—Methotrexate—esophageal cancer	0.000152	0.00268	CcSEcCtD
Montelukast—Skin disorder—Methotrexate—esophageal cancer	0.000151	0.00266	CcSEcCtD
Montelukast—Asthenia—Capecitabine—esophageal cancer	0.00015	0.00264	CcSEcCtD
Montelukast—Pruritus—Capecitabine—esophageal cancer	0.000148	0.0026	CcSEcCtD
Montelukast—Diarrhoea—Capecitabine—esophageal cancer	0.000143	0.00252	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000142	0.00249	CcSEcCtD
Montelukast—Insomnia—Methotrexate—esophageal cancer	0.000141	0.00247	CcSEcCtD
Montelukast—Paraesthesia—Methotrexate—esophageal cancer	0.00014	0.00246	CcSEcCtD
Montelukast—Somnolence—Methotrexate—esophageal cancer	0.000138	0.00243	CcSEcCtD
Montelukast—Dizziness—Capecitabine—esophageal cancer	0.000138	0.00243	CcSEcCtD
Montelukast—Dyspepsia—Methotrexate—esophageal cancer	0.000137	0.00241	CcSEcCtD
Montelukast—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000134	0.00236	CcSEcCtD
Montelukast—Fatigue—Methotrexate—esophageal cancer	0.000134	0.00236	CcSEcCtD
Montelukast—Pain—Methotrexate—esophageal cancer	0.000133	0.00234	CcSEcCtD
Montelukast—Vomiting—Capecitabine—esophageal cancer	0.000133	0.00234	CcSEcCtD
Montelukast—Rash—Capecitabine—esophageal cancer	0.000132	0.00232	CcSEcCtD
Montelukast—Dermatitis—Capecitabine—esophageal cancer	0.000132	0.00232	CcSEcCtD
Montelukast—Headache—Capecitabine—esophageal cancer	0.000131	0.0023	CcSEcCtD
Montelukast—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000127	0.00224	CcSEcCtD
Montelukast—Nausea—Capecitabine—esophageal cancer	0.000124	0.00218	CcSEcCtD
Montelukast—Urticaria—Methotrexate—esophageal cancer	0.000124	0.00217	CcSEcCtD
Montelukast—Abdominal pain—Methotrexate—esophageal cancer	0.000123	0.00216	CcSEcCtD
Montelukast—Body temperature increased—Methotrexate—esophageal cancer	0.000123	0.00216	CcSEcCtD
Montelukast—Hypersensitivity—Methotrexate—esophageal cancer	0.000115	0.00202	CcSEcCtD
Montelukast—Asthenia—Methotrexate—esophageal cancer	0.000112	0.00196	CcSEcCtD
Montelukast—Pruritus—Methotrexate—esophageal cancer	0.00011	0.00194	CcSEcCtD
Montelukast—Diarrhoea—Methotrexate—esophageal cancer	0.000106	0.00187	CcSEcCtD
Montelukast—Dizziness—Methotrexate—esophageal cancer	0.000103	0.00181	CcSEcCtD
Montelukast—Vomiting—Methotrexate—esophageal cancer	9.89e-05	0.00174	CcSEcCtD
Montelukast—Rash—Methotrexate—esophageal cancer	9.81e-05	0.00173	CcSEcCtD
Montelukast—Dermatitis—Methotrexate—esophageal cancer	9.8e-05	0.00172	CcSEcCtD
Montelukast—Headache—Methotrexate—esophageal cancer	9.74e-05	0.00171	CcSEcCtD
Montelukast—Nausea—Methotrexate—esophageal cancer	9.24e-05	0.00163	CcSEcCtD
Montelukast—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	7.05e-05	0.000718	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CTNNA1—esophageal cancer	6.76e-05	0.000688	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CXCL2—esophageal cancer	6.72e-05	0.000685	CbGpPWpGaD
Montelukast—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	6.7e-05	0.000682	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—ALDH2—esophageal cancer	6.63e-05	0.000675	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	6.6e-05	0.000672	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	6.46e-05	0.000658	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—BLVRB—esophageal cancer	6.43e-05	0.000655	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—SLC52A3—esophageal cancer	6.43e-05	0.000655	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—GSTT1—esophageal cancer	6.3e-05	0.000642	CbGpPWpGaD
Montelukast—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	6.29e-05	0.000641	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—PSME2—esophageal cancer	6.28e-05	0.000639	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—PSME1—esophageal cancer	6.28e-05	0.000639	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—ANXA1—esophageal cancer	6.25e-05	0.000636	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—CYP2A6—esophageal cancer	6.23e-05	0.000635	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	6.21e-05	0.000632	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	6.21e-05	0.000632	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—BLVRB—esophageal cancer	6.08e-05	0.00062	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—SLC52A3—esophageal cancer	6.08e-05	0.00062	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—SST—esophageal cancer	6.08e-05	0.000619	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—NOTCH3—esophageal cancer	5.92e-05	0.000603	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—GHRL—esophageal cancer	5.92e-05	0.000603	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—PTGS1—esophageal cancer	5.91e-05	0.000602	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—ENO1—esophageal cancer	5.91e-05	0.000602	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—FBXW7—esophageal cancer	5.83e-05	0.000594	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	5.83e-05	0.000593	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—PSME2—esophageal cancer	5.82e-05	0.000593	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—PSME1—esophageal cancer	5.82e-05	0.000593	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	5.54e-05	0.000564	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	5.48e-05	0.000558	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	5.48e-05	0.000558	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CA1—esophageal cancer	5.47e-05	0.000557	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—SLC10A2—esophageal cancer	5.47e-05	0.000557	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	5.36e-05	0.000546	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—NOTCH2—esophageal cancer	5.31e-05	0.000541	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	5.19e-05	0.000529	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CA1—esophageal cancer	5.17e-05	0.000527	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—SLC10A2—esophageal cancer	5.17e-05	0.000527	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	5.08e-05	0.000518	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—CYP1B1—esophageal cancer	5.02e-05	0.000511	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CA2—esophageal cancer	5e-05	0.000509	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	4.89e-05	0.000498	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CA2—esophageal cancer	4.73e-05	0.000482	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—CYP19A1—esophageal cancer	4.72e-05	0.000481	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—TGFBR2—esophageal cancer	4.71e-05	0.00048	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	4.68e-05	0.000476	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PLCE1—esophageal cancer	4.65e-05	0.000474	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—ADH7—esophageal cancer	4.65e-05	0.000474	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	4.6e-05	0.000468	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—SMAD4—esophageal cancer	4.46e-05	0.000454	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	4.42e-05	0.00045	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—ADH7—esophageal cancer	4.4e-05	0.000448	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PLCE1—esophageal cancer	4.4e-05	0.000448	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	4.36e-05	0.000444	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	4.35e-05	0.000443	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—HMOX1—esophageal cancer	4.31e-05	0.000439	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.23e-05	0.00043	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—SLC52A3—esophageal cancer	4.16e-05	0.000423	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—BLVRB—esophageal cancer	4.16e-05	0.000423	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	4.15e-05	0.000423	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—ABCB1—esophageal cancer	4.14e-05	0.000421	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	4.09e-05	0.000417	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—ADH1B—esophageal cancer	4.08e-05	0.000415	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—TYMP—esophageal cancer	3.9e-05	0.000397	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—ADH1B—esophageal cancer	3.86e-05	0.000393	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	3.81e-05	0.000388	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CYP26A1—esophageal cancer	3.79e-05	0.000386	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	3.72e-05	0.000378	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—ALOX15—esophageal cancer	3.7e-05	0.000376	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—TYMP—esophageal cancer	3.69e-05	0.000375	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—HIF1A—esophageal cancer	3.65e-05	0.000372	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CYP26A1—esophageal cancer	3.59e-05	0.000365	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CA1—esophageal cancer	3.53e-05	0.00036	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—SLC10A2—esophageal cancer	3.53e-05	0.00036	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—TPI1—esophageal cancer	3.53e-05	0.000359	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GSTO1—esophageal cancer	3.53e-05	0.000359	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—ALOX15—esophageal cancer	3.49e-05	0.000356	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—KDR—esophageal cancer	3.49e-05	0.000356	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—SLC52A3—esophageal cancer	3.38e-05	0.000344	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—BLVRB—esophageal cancer	3.38e-05	0.000344	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—ALDOB—esophageal cancer	3.38e-05	0.000344	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GSTO1—esophageal cancer	3.33e-05	0.000339	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—TPI1—esophageal cancer	3.33e-05	0.000339	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—NOTCH1—esophageal cancer	3.29e-05	0.000335	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GAPDH—esophageal cancer	3.25e-05	0.000331	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CA2—esophageal cancer	3.23e-05	0.000329	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CRABP1—esophageal cancer	3.22e-05	0.000328	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—ALDOB—esophageal cancer	3.2e-05	0.000325	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	3.16e-05	0.000322	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.13e-05	0.000318	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GAPDH—esophageal cancer	3.08e-05	0.000313	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GNG7—esophageal cancer	3.07e-05	0.000312	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CRABP1—esophageal cancer	3.05e-05	0.00031	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	3.02e-05	0.000308	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PLCE1—esophageal cancer	3e-05	0.000306	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—ADH7—esophageal cancer	3e-05	0.000306	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CREBBP—esophageal cancer	2.98e-05	0.000304	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	2.97e-05	0.000302	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—EGFR—esophageal cancer	2.93e-05	0.000298	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GNG7—esophageal cancer	2.9e-05	0.000295	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CA1—esophageal cancer	2.88e-05	0.000293	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—SLC10A2—esophageal cancer	2.88e-05	0.000293	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—ALDH2—esophageal cancer	2.87e-05	0.000293	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—PIK3CA—esophageal cancer	2.8e-05	0.000285	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—CREBBP—esophageal cancer	2.76e-05	0.000281	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GSTT1—esophageal cancer	2.73e-05	0.000278	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—ALDH2—esophageal cancer	2.72e-05	0.000277	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CYP2A6—esophageal cancer	2.7e-05	0.000275	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.69e-05	0.000274	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—NOS3—esophageal cancer	2.67e-05	0.000272	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—ADH1B—esophageal cancer	2.63e-05	0.000268	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CA2—esophageal cancer	2.63e-05	0.000268	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GSTT1—esophageal cancer	2.58e-05	0.000263	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	2.57e-05	0.000262	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—ENO1—esophageal cancer	2.56e-05	0.000261	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—PIK3CA—esophageal cancer	2.54e-05	0.000259	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PSME1—esophageal cancer	2.52e-05	0.000257	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PSME2—esophageal cancer	2.52e-05	0.000257	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—TYMP—esophageal cancer	2.52e-05	0.000256	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—ERBB2—esophageal cancer	2.5e-05	0.000254	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—NOS3—esophageal cancer	2.48e-05	0.000252	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CYP26A1—esophageal cancer	2.45e-05	0.000249	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PLCE1—esophageal cancer	2.45e-05	0.000249	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—ADH7—esophageal cancer	2.45e-05	0.000249	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—ENO1—esophageal cancer	2.42e-05	0.000247	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PTGS1—esophageal cancer	2.42e-05	0.000247	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	2.42e-05	0.000246	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—ALOX15—esophageal cancer	2.39e-05	0.000243	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PSME2—esophageal cancer	2.39e-05	0.000243	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PSME1—esophageal cancer	2.39e-05	0.000243	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GSTO1—esophageal cancer	2.28e-05	0.000232	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—TPI1—esophageal cancer	2.28e-05	0.000232	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—PTGS2—esophageal cancer	2.26e-05	0.000231	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—SLC52A3—esophageal cancer	2.23e-05	0.000227	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—BLVRB—esophageal cancer	2.23e-05	0.000227	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CCND1—esophageal cancer	2.21e-05	0.000225	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.2e-05	0.000224	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—ALDOB—esophageal cancer	2.18e-05	0.000222	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CYP1B1—esophageal cancer	2.18e-05	0.000222	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—ADH1B—esophageal cancer	2.14e-05	0.000218	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CDKN1A—esophageal cancer	2.13e-05	0.000217	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GAPDH—esophageal cancer	2.1e-05	0.000214	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CRABP1—esophageal cancer	2.08e-05	0.000212	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CYP1B1—esophageal cancer	2.06e-05	0.00021	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—TYMP—esophageal cancer	2.05e-05	0.000209	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CYP19A1—esophageal cancer	2.05e-05	0.000209	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—EP300—esophageal cancer	2.03e-05	0.000207	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CYP26A1—esophageal cancer	1.99e-05	0.000203	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GNG7—esophageal cancer	1.98e-05	0.000202	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—ALOX15—esophageal cancer	1.94e-05	0.000198	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CYP19A1—esophageal cancer	1.94e-05	0.000197	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—SLC10A2—esophageal cancer	1.9e-05	0.000193	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CA1—esophageal cancer	1.9e-05	0.000193	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—EP300—esophageal cancer	1.88e-05	0.000192	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—HMOX1—esophageal cancer	1.87e-05	0.00019	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—ALDH2—esophageal cancer	1.86e-05	0.000189	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—TPI1—esophageal cancer	1.85e-05	0.000189	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GSTO1—esophageal cancer	1.85e-05	0.000189	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.83e-05	0.000187	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—ABCB1—esophageal cancer	1.79e-05	0.000183	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—ALDOB—esophageal cancer	1.78e-05	0.000181	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—MYC—esophageal cancer	1.77e-05	0.00018	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—HMOX1—esophageal cancer	1.77e-05	0.00018	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GSTT1—esophageal cancer	1.77e-05	0.00018	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CYP2A6—esophageal cancer	1.75e-05	0.000178	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.74e-05	0.000177	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CA2—esophageal cancer	1.73e-05	0.000177	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—EGFR—esophageal cancer	1.73e-05	0.000176	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GAPDH—esophageal cancer	1.71e-05	0.000174	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—ABCB1—esophageal cancer	1.7e-05	0.000173	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CRABP1—esophageal cancer	1.7e-05	0.000173	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—ENO1—esophageal cancer	1.65e-05	0.000168	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PTGS1—esophageal cancer	1.65e-05	0.000168	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PSME1—esophageal cancer	1.63e-05	0.000166	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PSME2—esophageal cancer	1.63e-05	0.000166	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—ADH7—esophageal cancer	1.61e-05	0.000164	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.61e-05	0.000164	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GNG7—esophageal cancer	1.61e-05	0.000164	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—ALDH2—esophageal cancer	1.51e-05	0.000154	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—PIK3CA—esophageal cancer	1.5e-05	0.000153	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—TP53—esophageal cancer	1.45e-05	0.000148	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GSTT1—esophageal cancer	1.44e-05	0.000146	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.42e-05	0.000145	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CYP2A6—esophageal cancer	1.42e-05	0.000145	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.41e-05	0.000144	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.41e-05	0.000144	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CYP1B1—esophageal cancer	1.41e-05	0.000143	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—PIK3CA—esophageal cancer	1.39e-05	0.000142	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.36e-05	0.000138	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—TYMP—esophageal cancer	1.35e-05	0.000138	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—ENO1—esophageal cancer	1.35e-05	0.000137	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PTGS1—esophageal cancer	1.35e-05	0.000137	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PSME2—esophageal cancer	1.33e-05	0.000135	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PSME1—esophageal cancer	1.33e-05	0.000135	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CYP19A1—esophageal cancer	1.32e-05	0.000135	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.31e-05	0.000134	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.28e-05	0.00013	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—TPI1—esophageal cancer	1.22e-05	0.000124	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.22e-05	0.000124	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—HMOX1—esophageal cancer	1.21e-05	0.000123	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CREBBP—esophageal cancer	1.2e-05	0.000122	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.18e-05	0.000121	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.17e-05	0.000119	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.16e-05	0.000118	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—ABCB1—esophageal cancer	1.16e-05	0.000118	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CYP1B1—esophageal cancer	1.14e-05	0.000117	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CREBBP—esophageal cancer	1.13e-05	0.000115	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.13e-05	0.000115	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.12e-05	0.000114	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CYP19A1—esophageal cancer	1.08e-05	0.00011	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—NOS3—esophageal cancer	1.07e-05	0.000109	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GNG7—esophageal cancer	1.06e-05	0.000108	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—NOS3—esophageal cancer	1.01e-05	0.000103	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—ALDH2—esophageal cancer	9.96e-06	0.000101	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—HMOX1—esophageal cancer	9.82e-06	0.0001	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PTGS2—esophageal cancer	9.82e-06	9.99e-05	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	9.64e-06	9.81e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GSTT1—esophageal cancer	9.48e-06	9.65e-05	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—ABCB1—esophageal cancer	9.43e-06	9.6e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CYP2A6—esophageal cancer	9.37e-06	9.54e-05	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PTGS2—esophageal cancer	9.28e-06	9.45e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—ENO1—esophageal cancer	8.88e-06	9.04e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PTGS1—esophageal cancer	8.88e-06	9.04e-05	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	8.76e-06	8.92e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PSME2—esophageal cancer	8.75e-06	8.91e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PSME1—esophageal cancer	8.75e-06	8.91e-05	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—EP300—esophageal cancer	8.16e-06	8.31e-05	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CREBBP—esophageal cancer	7.74e-06	7.88e-05	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—EP300—esophageal cancer	7.72e-06	7.86e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CYP1B1—esophageal cancer	7.55e-06	7.69e-05	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.13e-06	7.26e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CYP19A1—esophageal cancer	7.1e-06	7.23e-05	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—NOS3—esophageal cancer	6.93e-06	7.06e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—HMOX1—esophageal cancer	6.48e-06	6.6e-05	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PTGS2—esophageal cancer	6.34e-06	6.46e-05	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CREBBP—esophageal cancer	6.3e-06	6.42e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—ABCB1—esophageal cancer	6.22e-06	6.33e-05	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PIK3CA—esophageal cancer	6.04e-06	6.15e-05	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PIK3CA—esophageal cancer	5.71e-06	5.81e-05	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—NOS3—esophageal cancer	5.64e-06	5.74e-05	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—EP300—esophageal cancer	5.27e-06	5.37e-05	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PTGS2—esophageal cancer	5.16e-06	5.25e-05	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—EP300—esophageal cancer	4.29e-06	4.37e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CREBBP—esophageal cancer	4.16e-06	4.23e-05	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PIK3CA—esophageal cancer	3.9e-06	3.97e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—NOS3—esophageal cancer	3.72e-06	3.79e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PTGS2—esophageal cancer	3.4e-06	3.47e-05	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PIK3CA—esophageal cancer	3.17e-06	3.23e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—EP300—esophageal cancer	2.83e-06	2.88e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.09e-06	2.13e-05	CbGpPWpGaD
